D-0485-2026 Class II Ongoing

Recalled by The Harvard Drug Group LLC — Dublin, OH

FDA drug recall D-0485-2026 was initiated by The Harvard Drug Group LLC on Mar 24, 2026 and is designated Class II. Reason for recall: Failed Dissolution Specifications The recall status is ongoing.

Recall details

Product Type
Drugs
Report Date
Apr 22, 2026
Initiation Date
Mar 24, 2026
Voluntary/Mandated
Voluntary: Firm initiated

Product description

Memantine Hydrochloride Extended-Release, Capsules, 7 mg, 100 Capsules (10 x 10 blister packs), Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268, NDC 0904-6734-61

Reason for recall

Failed Dissolution Specifications

Distribution pattern

US Nationwide.

Code information

Lot # N02425, Exp Date: 05/31/2027.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0485-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0485-2026. Report a data issue: hello@regdatalab.com.